Huntington Disease
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
|
16604191 |
2006 |
Motor Neuron Disease, Lower
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, this mutation causing a loss-of-function of HSJ1 is linked to a pure lower motor neuron disease, strongly suggesting that HSJ1 also plays an important and specific role in motor neurons.
|
22522442 |
2012 |
Hereditary Motor and Sensory-Neuropathy Type II
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Taken together, in our cohort of 90 probands, we confirm that HSJ1 mutations are a rare but detectable cause of autosomal recessive dHMN and CMT2.
|
25274842 |
2014 |
Bulbo-Spinal Atrophy, X-Linked
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DNAJB2 functions as an adaptor molecule for the evacuation and degradation of proteins through the ubiquitin-proteasome system, and overexpression of DNAJB2 in models of the neurodegenerative disease spinobulbar muscular atrophy was shown to result in the reduction of protein inclusions.
|
20395441 |
2010 |
Amyotrophy, monomelic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sporadic juvenile muscular atrophy of the distal upper extremity or Hirayama's disease (HD) and autosomal dominant motor distal neuronopathy/axonopathy (CMT2D/dSMA-V), produced by glycyl-tRNA synthetase (GARS) gene mutations, share some clinical features including: young age of onset, predilection for the distal upper extremity, asymmetry, sparing of proximal muscles and unusual cold sensitivity.
|
19412816 |
2010 |
Absent reflex
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Skeletal muscle atrophy
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Distal sensory impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Slow progression
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Foot dorsiflexor weakness
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Gait Disturbance, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Gait abnormality
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Neurodegenerative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
They also suggest that CK2 inhibitors could release the full neuroprotective potential of HSJ1, and deserve future interest as therapeutic strategies for neurodegenerative disease.
|
28031292 |
2017 |
Neurodegenerative Disorders
|
0.020 |
AlteredExpression
|
group |
BEFREE |
DNAJB2 functions as an adaptor molecule for the evacuation and degradation of proteins through the ubiquitin-proteasome system, and overexpression of DNAJB2 in models of the neurodegenerative disease spinobulbar muscular atrophy was shown to result in the reduction of protein inclusions.
|
20395441 |
2010 |
Myopathy
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We conclude that DNAJB2 is expressed in mouse and human skeletal muscle at the neuromuscular junction of normal fibers, in the cytoplasm and membrane of regenerating fibers, and in protein aggregates and vacuoles in protein aggregate myopathies.
|
20395441 |
2010 |
Hereditary Motor and Sensory Neuropathies
|
0.010 |
GeneticVariation
|
group |
BEFREE |
To determine the nature and frequency of HSJ1 mutations in patients with hereditary motor and hereditary motor and sensory neuropathies.
|
25274842 |
2014 |
Parkinsonian Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Identification of a Large DNAJB2 Deletion in a Family with Spinal Muscular Atrophy and Parkinsonism.
|
27449489 |
2016 |
Neuropathy
|
0.010 |
Biomarker
|
group |
BEFREE |
We provide clinical and functional information on an HSJ1 splice-site mutation and report the detailed phenotype of 2 patients with CMT2, broadening the phenotypic spectrum of HSJ1-related neuropathies.
|
25274842 |
2014 |